<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="167974">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01656499</url>
  </required_header>
  <id_info>
    <org_study_id>ML7245</org_study_id>
    <nct_id>NCT01656499</nct_id>
  </id_info>
  <brief_title>Effect of AXOS on the Colon Metabolism in Healthy Volunteers</brief_title>
  <official_title>Effect of AXOS on the Colon Metabolism in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of AXOS on parameters of colon
      metabolism and gut health
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Fecal water toxicity</measure>
    <time_frame>Participants are followed for 10 weeks, with measurements on 4 specific time points</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Gut Health</condition>
  <arm_group>
    <arm_group_label>Arabinoxylanoligosaccharides (AXOS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AXOS (2 x 5g WBE/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maltodextrine (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrine (2 x 5g/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Arabinoxylanoligosaccharides</intervention_name>
    <arm_group_label>Arabinoxylanoligosaccharides (AXOS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrine</intervention_name>
    <arm_group_label>Maltodextrine (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers

          -  regular dietary pattern (3 meals/day)

          -  age: 18-45y

          -  BMI: 18,5-27 kg/m2

        Exclusion Criteria:

          -  intake of antibiotics 1 month prior to the study

          -  abdominal surgery in the past, with the exception of appendectomy

          -  intake of medication influencing the gastro-intestinal system 14 days prior to the
             study

          -  in treatment at a dietician

          -  serious liver- or kidney failure

          -  vegetarians

          -  intake of pre- and/or probiotics

          -  Exposure to radioactivity 1 year prior to the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Leuven/KU Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 1, 2012</lastchanged_date>
  <firstreceived_date>July 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Kristin Verbeke</investigator_full_name>
    <investigator_title>Professor Kristin Verbeke, Ph. D.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
